229 related articles for article (PubMed ID: 31604164)
1. Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; Omar FA
Eur J Med Chem; 2019 Dec; 184():111747. PubMed ID: 31604164
[TBL] [Abstract][Full Text] [Related]
2. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
[TBL] [Abstract][Full Text] [Related]
3. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
[TBL] [Abstract][Full Text] [Related]
5. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study.
Elfiky AA
Med Chem; 2019; 15(2):130-137. PubMed ID: 30324891
[TBL] [Abstract][Full Text] [Related]
6. Molecular design and synthesis of HCV inhibitors based on thiazolone scaffold.
Al-Ansary GH; Ismail MA; Abou El Ella DA; Eid S; Abouzid KA
Eur J Med Chem; 2013 Oct; 68():19-32. PubMed ID: 23933047
[TBL] [Abstract][Full Text] [Related]
7. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
[TBL] [Abstract][Full Text] [Related]
8. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of L- and D-phenylalanine derived rhodanines with novel C5-arylidenes as inhibitors of HCV NS5B polymerase.
Patel BA; Krishnan R; Khadtare N; Gurukumar KR; Basu A; Arora P; Bhatt A; Patel MR; Dana D; Kumar S; Kaushik-Basu N; Talele TT
Bioorg Med Chem; 2013 Jun; 21(11):3262-71. PubMed ID: 23598249
[TBL] [Abstract][Full Text] [Related]
10. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.
Talele TT; Arora P; Kulkarni SS; Patel MR; Singh S; Chudayeu M; Kaushik-Basu N
Bioorg Med Chem; 2010 Jul; 18(13):4630-8. PubMed ID: 20627595
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.
Wei Y; Li J; Qing J; Huang M; Wu M; Gao F; Li D; Hong Z; Kong L; Huang W; Lin J
PLoS One; 2016; 11(2):e0148181. PubMed ID: 26845440
[TBL] [Abstract][Full Text] [Related]
12. HCVpred: A web server for predicting the bioactivity of hepatitis C virus NS5B inhibitors.
Malik AA; Phanus-Umporn C; Schaduangrat N; Shoombuatong W; Isarankura-Na-Ayudhya C; Nantasenamat C
J Comput Chem; 2020 Jul; 41(20):1820-1834. PubMed ID: 32449536
[TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization and derivatization of 2-substituted quinolone-based non-nucleoside HCV NS5B inhibitors with submicromolar cellular replicon potency.
Cheng Y; Shen J; Peng RZ; Wang GF; Zuo JP; Long YQ
Bioorg Med Chem Lett; 2016 Jun; 26(12):2900-2906. PubMed ID: 27133482
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase.
Khalid H; Landry KB; Ijaz B; Ashfaq UA; Ahmed M; Kanwal A; Froeyen M; Mirza MU
Infect Genet Evol; 2020 Oct; 84():104371. PubMed ID: 32485331
[TBL] [Abstract][Full Text] [Related]
15. 4-Thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors.
Kaushik-Basu N; Bopda-Waffo A; Talele TT; Basu A; Chen Y; Kucukguzel SG
Front Biosci; 2008 May; 13():3857-68. PubMed ID: 18508480
[TBL] [Abstract][Full Text] [Related]
16. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
Qin Z; Wang M; Yan A
Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of Taraxacum officinale against HCV NS5B polymerase: In-vitro and In silico study.
Rehman S; Ijaz B; Fatima N; Muhammad SA; Riazuddin S
Biomed Pharmacother; 2016 Oct; 83():881-891. PubMed ID: 27513212
[TBL] [Abstract][Full Text] [Related]
18. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
Yu H; Fang Y; Lu X; Liu Y; Zhang H
Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
20. The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors.
Manfroni G; Cannalire R; Barreca ML; Kaushik-Basu N; Leyssen P; Winquist J; Iraci N; Manvar D; Paeshuyse J; Guhamazumder R; Basu A; Sabatini S; Tabarrini O; Danielson UH; Neyts J; Cecchetti V
J Med Chem; 2014 Mar; 57(5):1952-63. PubMed ID: 24131104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
